β¨ Medicines Notices
NEW ZEALAND GAZETTE, No. 52
13 MAY 2004
Provisional Consent to the Distribution of New Medicines
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product:
Benztrop
Active Ingredient:
Benzatropine mesilate 2mg
Dosage Form:
Tablet
New Zealand Sponsor:
AFT Pharmaceuticals Limited
Manufacturer:
Pharmascience Inc, Montreal, Quebec, Canada
Note: This consent is valid for two years from the date of publication of this notice.
Product:
Luveris
Active Ingredient:
Lutropin alfa, rch 75IU
Dosage Form:
Powder for injection
New Zealand Sponsor:
Douglas Pharmaceuticals Limited
Manufacturer:
Laboratories Serono SA, Aubonne, Switzerland
Note: This consent is valid for two years from the date of publication of this notice.
Dated this 2nd day of May 2004.
DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on the 6th day of July 2001).
go2963
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product:
Blink Revitalising Eye Drops
Active Ingredients:
Hypromellose 1.5mg/mL
Trometamol 12mg/mL
Tyloxapol 0.25mg/mL
Dosage Form:
Contact lens solution
New Zealand Sponsor:
Advanced Medical Optics Australia Pty Limited
Manufacturer:
Allergan Pharmaceuticals Ireland, Westport, County Mayo, Eire
Product:
Myfortic
Active Ingredient:
Mycophenolate sodium 192.4mg equivalent to mycophenolic acid 180mg
Dosage Form:
Enteric coated tablet
New Zealand Sponsor:
Novartis New Zealand Limited
Manufacturer:
Novartis Pharma Stein AG, Stein, Switzerland
Product:
Myfortic
Active Ingredient:
Mycophenolate sodium 384.8mg equivalent to mycophenolic acid 360mg
Dosage Form:
Enteric coated tablet
New Zealand Sponsor:
Novartis New Zealand Limited
Manufacturer:
Novartis Pharma Stein AG, Stein, Switzerland
Product:
Obix
Active Ingredient:
Orlistat 120mg
Dosage Form:
Capsule
New Zealand Sponsor:
Roche Products (New Zealand) Limited
Manufacturers:
F Hoffmann-La Roche Ltd, Basel, Switzerland
Hoffmann-La Roche Inc, Nutley, New Jersey, United States of America
Roche Prodotti SpA, Segrate, Milan, Italy
Dated this 2nd day of May 2004.
DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on the 6th day of July 2001).
go2964
Revocation of Prohibition From Prescribing Medicines
Pursuant to section 48 (3) of the Medicines Act 1981,
I, Annette King, Minister of Health, hereby revoke the notice issued on 26 May 1993 and published in
the New Zealand Gazette, 10 June 1993, page 1515, that prohibits
Dr Saba La Hood, medical practitioner of Wellington
from prescribing benzodiazepines and their derivatives.
Dated at Wellington this 4th day of May 2004.
ANNETTE KING, Minister of Health.
go3048
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2004, No 52
Gazette.govt.nz —
NZ Gazette 2004, No 52
β¨ LLM interpretation of page content
π₯ Provisional Consent to Distribution of New Medicines
π₯ Health & Social Welfare2 May 2004
Medicines, Provisional Consent, Benztrop, Luveris, Benzatropine mesilate, Lutropin alfa
- DON MATHESON, Deputy Director-General, Public Health
π₯ Consent to Distribution of New Medicines
π₯ Health & Social Welfare2 May 2004
Medicines, Consent, Blink Revitalising Eye Drops, Myfortic, Obix, Hypromellose, Mycophenolate sodium, Orlistat
- DON MATHESON, Deputy Director-General, Public Health
π₯ Revocation of Prohibition From Prescribing Medicines
π₯ Health & Social Welfare4 May 2004
Medicines, Revocation, Prohibition, Benzodiazepines, Medical Practitioner
- Saba La Hood (Dr), Revoked prohibition from prescribing benzodiazepines
- ANNETTE KING, Minister of Health